18 F-FDG PET/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer

• Published in: Journal of Cancer 2021, Vol.12 (19), p.5838-5847
• Main Authors: Yang, Jian-Wei, Yuan, Ling-Ling, Gao, Yan, Liu, Xu-Sheng, Wang, Yu-Jiao, Zhou, Lu-Meng, Kui, Xue-Yan, Li, Xiao-Hui, Ke, Chang-Bin, Pei, Zhi-Jun
• Format: Article
• Language: English
• ISSN: 1837-9664; 1837-9664
• DOI: 10.7150/jca.57926

We sought to investigate whether the expression of the gene EIF2S2 is related to F-FDG PET/CT metabolic parameters in patients with colorectal cancer (CRC). The expression of EIF2S2 in CRC and its relationship with clinicopathological features were obtained through the ONCOMINE, UALCAN and GEPIA databases. EIF2S2 and GLUT1 expression were examined by immunohistochemistry in 42 CRC patients undergoing preoperative PET-CT examination. Spearman correlation analysis was used to assess the relationship between EIF2S2 and GLUT1 levels and clinical parameters. Correlation analysis between EIF2S2 and Reactome-Glycolysis signatures was performed using GEPIA2. We describe the effect of EIF2S2 knockdown on lactate production and the mRNA levels of glycolysis-related genes in human colon cancer SW480 cells. Immunohistochemistry revealed an upregulation of EIF2S2 protein expression in tumor tissues of colorectal cancer patients, which is consistent with the significant upregulation of EIF2S2 transcript levels in the database. These colorectal cancer patients included 24 cases of colon cancer and 18 cases of rectal cancer, ranging in age from 31 to 78 years. The transcription was significantly related to histological subtypes and TP53 mutations (P